JP2003531857A - アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用 - Google Patents
アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用Info
- Publication number
- JP2003531857A JP2003531857A JP2001579803A JP2001579803A JP2003531857A JP 2003531857 A JP2003531857 A JP 2003531857A JP 2001579803 A JP2001579803 A JP 2001579803A JP 2001579803 A JP2001579803 A JP 2001579803A JP 2003531857 A JP2003531857 A JP 2003531857A
- Authority
- JP
- Japan
- Prior art keywords
- alzheimer
- carnitine
- loss
- dementia
- cognitive function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 117
- 230000004060 metabolic process Effects 0.000 title claims abstract description 46
- 230000001537 neural effect Effects 0.000 title claims description 35
- 229940057917 medium chain triglycerides Drugs 0.000 title claims description 25
- 230000003247 decreasing effect Effects 0.000 title abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 14
- 201000010099 disease Diseases 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 39
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 33
- 239000000194 fatty acid Substances 0.000 claims abstract description 33
- 229930195729 fatty acid Natural products 0.000 claims abstract description 33
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 33
- 230000003920 cognitive function Effects 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 238000011161 development Methods 0.000 claims abstract description 7
- 150000002576 ketones Chemical class 0.000 claims description 51
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 29
- 230000002829 reductive effect Effects 0.000 claims description 23
- 230000002265 prevention Effects 0.000 claims description 22
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 20
- 230000003292 diminished effect Effects 0.000 claims description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 235000021588 free fatty acids Nutrition 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000007976 Ketosis Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000004140 ketosis Effects 0.000 claims description 3
- 238000011260 co-administration Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 abstract description 27
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 4
- 206010039966 Senile dementia Diseases 0.000 abstract description 2
- 230000003931 cognitive performance Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- 239000008103 glucose Substances 0.000 description 27
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 230000004153 glucose metabolism Effects 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 101150037123 APOE gene Proteins 0.000 description 9
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 210000001130 astrocyte Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000037259 Amyloid Plaque Diseases 0.000 description 7
- 230000035508 accumulation Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 6
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 6
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000035861 hyperketonemia Effects 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000007082 Aβ accumulation Effects 0.000 description 5
- 102000003746 Insulin Receptor Human genes 0.000 description 5
- 108010001127 Insulin Receptor Proteins 0.000 description 5
- 108010036933 Presenilin-1 Proteins 0.000 description 5
- 102000012412 Presenilin-1 Human genes 0.000 description 5
- 102000012419 Presenilin-2 Human genes 0.000 description 5
- 108010036908 Presenilin-2 Proteins 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 3
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- LZOSYCMHQXPBFU-OAHLLOKOSA-N O-decanoyl-L-carnitine Chemical compound CCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LZOSYCMHQXPBFU-OAHLLOKOSA-N 0.000 description 1
- LZOSYCMHQXPBFU-UHFFFAOYSA-N O-decanoylcarnitine Chemical compound CCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C LZOSYCMHQXPBFU-UHFFFAOYSA-N 0.000 description 1
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 description 1
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical compound CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 description 1
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 1
- CXTATJFJDMJMIY-UHFFFAOYSA-N O-octanoylcarnitine Chemical compound CCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C CXTATJFJDMJMIY-UHFFFAOYSA-N 0.000 description 1
- PSHXNVGSVNEJBD-LJQANCHMSA-N O-tetradecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C PSHXNVGSVNEJBD-LJQANCHMSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091006298 SLC2A3 Proteins 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 102100022722 Solute carrier family 2, facilitated glucose transporter member 3 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- XOMRRQXKHMYMOC-OAQYLSRUSA-O [(2r)-3-carboxy-2-hexadecanoyloxypropyl]-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C XOMRRQXKHMYMOC-OAQYLSRUSA-O 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002361 ketogenic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20098000P | 2000-05-01 | 2000-05-01 | |
| US60/200,980 | 2000-05-01 | ||
| PCT/US2001/013955 WO2001082928A1 (en) | 2000-05-01 | 2001-05-01 | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012105692A Division JP5701245B2 (ja) | 2000-05-01 | 2012-05-07 | アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003531857A true JP2003531857A (ja) | 2003-10-28 |
| JP2003531857A5 JP2003531857A5 (https=) | 2008-03-13 |
Family
ID=22743976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001579803A Pending JP2003531857A (ja) | 2000-05-01 | 2001-05-01 | アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用 |
| JP2012105692A Expired - Lifetime JP5701245B2 (ja) | 2000-05-01 | 2012-05-07 | アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012105692A Expired - Lifetime JP5701245B2 (ja) | 2000-05-01 | 2012-05-07 | アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20020006959A1 (https=) |
| EP (3) | EP2319508A1 (https=) |
| JP (2) | JP2003531857A (https=) |
| AT (1) | ATE425750T1 (https=) |
| AU (1) | AU2001257451A1 (https=) |
| DE (1) | DE60138019D1 (https=) |
| DK (1) | DK1292294T3 (https=) |
| ES (2) | ES2752800T3 (https=) |
| PT (1) | PT1292294E (https=) |
| WO (1) | WO2001082928A1 (https=) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009524587A (ja) * | 2005-12-15 | 2009-07-02 | ネステク ソシエテ アノニム | 脳機能を維持するための組成物及び方法 |
| JP2009532496A (ja) * | 2006-04-03 | 2009-09-10 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
| JP2010535037A (ja) * | 2007-07-31 | 2010-11-18 | アクセラ・インコーポレーテッド | 認知機能減少の治療のためのゲノム試験およびケトン体生成化合物の使用 |
| JP2011528667A (ja) * | 2008-07-18 | 2011-11-24 | ダート ニューロサイエンス エルエルシー | 記憶剤の評価のための方法およびシステム |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| US9028877B2 (en) | 2007-03-28 | 2015-05-12 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
| JP2015110626A (ja) * | 2009-12-30 | 2015-06-18 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | アルツハイマー病と加齢脳に対する補充療法 |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| JP2017505786A (ja) * | 2014-02-11 | 2017-02-23 | ファーネクストＰｈａｒｎｅｘｔ | 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用 |
| US9603823B2 (en) | 2000-05-01 | 2017-03-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| JP2019500024A (ja) * | 2015-12-04 | 2019-01-10 | ネステク ソシエテ アノニム | 認知を改善するための方法 |
| KR20200132950A (ko) * | 2018-03-15 | 2020-11-25 | 세레신 인코포레이티드 | 높은 약물 로딩의 중쇄 트리글리세라이드를 갖는 약학적 조성물 및 이와 관련된 방법 |
| JP2021107394A (ja) * | 2012-06-15 | 2021-07-29 | ヴィタフロ （インターナショナル） リミテッドＶｉｔａｆｌｏ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） Ｌｔｄ | 栄養製品 |
| JP2022523550A (ja) * | 2019-03-04 | 2022-04-25 | セレシン・インコーポレーテッド | バイオアベイラビリティが改善した中鎖脂肪酸トリグリセリド製剤およびそれに関連する方法 |
| JP2023534919A (ja) * | 2020-07-23 | 2023-08-15 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 認知機能を改善させるためのｍｃｔ配合物、並びにかかる配合物の製造及び使用方法 |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| US20020006959A1 (en) | 2000-05-01 | 2002-01-17 | Henderson Samuel T. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism |
| US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
| EP1605950A4 (en) * | 2003-03-06 | 2008-01-09 | Accera Inc | NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS |
| GB0306394D0 (en) | 2003-03-20 | 2003-04-23 | Univ Nottingham | Carnitine retention |
| EP1648952B1 (en) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| WO2006020179A2 (en) | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
| US20070281892A1 (en) * | 2004-09-21 | 2007-12-06 | Martin Keith F | Dopaminergic Mimetics |
| US7702343B2 (en) * | 2005-04-04 | 2010-04-20 | Qualcomm Incorporated | Efficient gap allocation for cell measurements in asynchronous communication networks |
| US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
| FR2885491B1 (fr) * | 2005-05-16 | 2020-03-06 | Nutricos Technologies | Traitement de la secheresse keratinique par des glycerides |
| EP1915144A4 (en) * | 2005-06-20 | 2009-08-19 | Accera Inc | METHOD FOR REDUCING OXIDATIVE DAMAGE AND IMPROVING MITOCHONDRIA EFFICIENCY |
| CA2637806A1 (en) * | 2005-11-07 | 2007-05-18 | Russell M. Jaffe | Compositions for regulating metabolic disorders and methods of use thereof |
| EP1929995A1 (en) | 2006-12-04 | 2008-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anaplerotic therapy of Huntington disease and other polyglutamine diseases |
| EP3050568B1 (en) * | 2007-03-13 | 2020-12-02 | JDS Therapeutics, LLC | Methods and compositions for the sustained release of chromium |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| JP2010527360A (ja) * | 2007-05-14 | 2010-08-12 | ニューエラ・ファーマシューティカルズ・インコーポレーテッド | 神経細胞の代謝低下の処置のためのアセチル−ｃｏａカルボキシラーゼの阻害剤 |
| WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
| ES2808406T3 (es) | 2007-06-26 | 2021-02-26 | Nutricia Nv | Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26 |
| ES2697149T3 (es) | 2007-12-20 | 2019-01-22 | Nutricia Nv | Producto líquido que contiene nucleótidos/nucleósidos |
| DK2240017T3 (da) | 2008-01-04 | 2019-06-17 | Univ Oxford Innovation Ltd | Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler |
| US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
| US8349376B1 (en) * | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| WO2013033074A2 (en) | 2011-08-31 | 2013-03-07 | St. Jude Children's Research Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| EP2914251B1 (en) | 2012-11-05 | 2019-08-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
| CA2894456C (en) | 2012-12-13 | 2022-06-28 | Baylor Research Institute | Triheptanoin for the treatment of glucose transporter 1 deficiency |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| SG11201507685UA (en) | 2013-03-14 | 2015-10-29 | Isis Innovation | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
| KR102499654B1 (ko) | 2013-03-19 | 2023-02-13 | 유니버시티 오브 사우스 플로리다 | 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법 |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| ES2774321T3 (es) | 2013-11-14 | 2020-07-20 | Univ Queensland | Trastornos neurodegenerativos y métodos de tratamiento y diagnóstico de los mismos |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| AU2015358958B2 (en) | 2014-12-08 | 2020-10-01 | Société des Produits Nestlé S.A. | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
| US10668041B2 (en) | 2014-12-08 | 2020-06-02 | Societe Des Produits Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
| ES2937960T5 (en) | 2015-02-11 | 2026-02-16 | Aker Biomarine Human Ingredients As | Lipid extraction processes |
| EP3256553A2 (en) | 2015-02-11 | 2017-12-20 | Aker Biomarine Antarctic AS | Lipid compositions |
| US11000496B2 (en) | 2015-12-04 | 2021-05-11 | Societe Des Produits Nestle S.A. | Medium chain triglyceride compositions |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US10736548B2 (en) * | 2016-05-18 | 2020-08-11 | Invoy Holdings, Inc. | Ketone measurement system for monitoring medical conditions |
| MX2018015188A (es) | 2016-06-08 | 2019-08-21 | Sunregen Healthcare Ag | Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional. |
| JP7246843B2 (ja) * | 2016-08-26 | 2023-03-28 | 日油株式会社 | スポーツ飲料 |
| EP3595638A4 (en) | 2017-03-15 | 2020-09-16 | Cerecin Inc. | PHARMACEUTICAL COMPOSITIONS WITH HIGH DRUG LOADS BASED ON MEDIUM-CHAIN TRIGLYCERIDES AND RELATED METHODS |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| CN116322659A (zh) * | 2020-10-09 | 2023-06-23 | 睿升公司 | 递送具有受控药物动力学、安全性和耐受性特性的中链甘油三酯的方法 |
| CU24748B1 (es) | 2022-11-04 | 2025-04-04 | Centro Nac De Biopreparados | Nutracéutico para la prevención y tratamiento del deterioro cognitivo |
| CN118340207A (zh) * | 2024-05-10 | 2024-07-16 | 华中农业大学 | 一种防治老年痴呆症的食用油脂及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0597785A (ja) * | 1990-02-23 | 1993-04-20 | Sigma Tau Ind Farmaceut Riunite Spa | （Ｒ）（−）−カルニチンおよびアシル−（Ｒ）（−）カルニチンとβ−ヒドロキシ酪酸とのエステル |
| JPH06287138A (ja) * | 1993-04-02 | 1994-10-11 | Green Cross Corp:The | アルツハイマー病予防治療剤 |
| WO1998041201A1 (en) * | 1997-03-17 | 1998-09-24 | Btg International Limited | Therapeutic compositions |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2766146A (en) * | 1954-07-26 | 1956-10-09 | Reynolds Tobacco Co R | Tobacco |
| US2766145A (en) * | 1954-07-26 | 1956-10-09 | Reynolds Tobacco Co R | Tobacco |
| US3053677A (en) * | 1959-11-12 | 1962-09-11 | Eastman Kodak Co | Petroleum wax for paper coatings |
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| FR2490631A1 (fr) * | 1980-09-24 | 1982-03-26 | Roussel Uclaf | Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique |
| US4528197A (en) | 1983-01-26 | 1985-07-09 | Kabivitrum Ab | Controlled triglyceride nutrition for hypercatabolic mammals |
| US4551523A (en) * | 1983-04-14 | 1985-11-05 | Eastman Kodak Company | Preparation of saccharide acetoacetates |
| US4847296A (en) | 1984-09-13 | 1989-07-11 | Babayan Vigen K | Triglyceride preparations for the prevention of catabolism |
| US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
| SE8803141L (sv) | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Naeringsmedel foer maenniskor och djur |
| US5650148A (en) | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
| DE3843238C1 (https=) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE69108239T2 (de) | 1990-04-26 | 1995-09-28 | Procter & Gamble | Polyol-fettsäure-polyester enthaltende backfettzusammensetzungen. |
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| GB9113484D0 (en) | 1991-06-21 | 1991-08-07 | Unilever Plc | Cosmetic composition |
| US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
| JP3265577B2 (ja) * | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白ｅの４型イソ型の測定法 |
| US5420335A (en) | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
| US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
| JP3645580B2 (ja) | 1993-10-22 | 2005-05-11 | 株式会社フジモト・ブラザーズ | グルコースエステル誘導体を含有する脳代謝改善剤 |
| US5691325A (en) | 1994-01-14 | 1997-11-25 | Sandyk; Reuven | Method for ameliorating age-related disease conditions |
| US7049078B2 (en) * | 1994-04-27 | 2006-05-23 | Judés Poirier | Apolipoprotein E polymorphism and treatment of alzheimer's disease |
| GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
| US5607967A (en) | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| ATE332127T1 (de) | 1994-11-08 | 2006-07-15 | Avicena Group Inc | Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose |
| US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
| US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
| JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| US5936078A (en) | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| DE19609476A1 (de) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen |
| IT1284650B1 (it) | 1996-05-24 | 1998-05-21 | Sigma Tau Ind Farmaceuti | Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia |
| KR980008239A (ko) * | 1996-07-26 | 1998-04-30 | 김충환 | 사이클로스포린-함유 약학적 조성물 |
| EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
| US6316038B1 (en) * | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US6352722B1 (en) | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
| US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
| WO1999051097A1 (en) | 1998-04-02 | 1999-10-14 | Avicena Group, Inc. | Compositions containing a combination of a creatine compound and a second agent |
| US6380244B2 (en) | 1998-07-22 | 2002-04-30 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| US6395306B1 (en) * | 1998-09-14 | 2002-05-28 | Pan Pacific Pharmaceuticals, Inc. | Bee venom protein and gene encoding same |
| WO2000015216A1 (en) * | 1998-09-15 | 2000-03-23 | Btg International Limited | Therapeutic compositions (ii) |
| GB9908202D0 (en) | 1999-04-12 | 1999-06-02 | Unilever Plc | Cosmetic compositions |
| US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
| US8124589B2 (en) * | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US20020006959A1 (en) | 2000-05-01 | 2002-01-17 | Henderson Samuel T. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism |
| DE20012857U1 (de) * | 2000-07-27 | 2000-11-09 | Sportmedizin Team Vertriebs Gmbh, Berneck | Diätetisches Lebensmittel zum Fettabbau |
| US6667397B2 (en) | 2000-08-25 | 2003-12-23 | Eastman Chemical Company | Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom |
| GB2368011A (en) | 2000-10-17 | 2002-04-24 | Unilever Plc | Fatty acid esters of maltose and uses thereof |
| US20020103139A1 (en) * | 2000-12-01 | 2002-08-01 | M. Weisspapir | Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control |
| KR100479741B1 (ko) | 2000-12-30 | 2005-03-30 | 주식회사 엘지생활건강 | 글루코오스 아실화 유도체 또는 수크로오스 아실화유도체를 함유하는 피부미백제 |
| WO2002098398A1 (en) * | 2001-06-07 | 2002-12-12 | Eisai Co., Ltd. | Methods for preventing and treating diseases and conditions associated with cellular stress |
| US20030059824A1 (en) * | 2001-09-21 | 2003-03-27 | Accera, Inc. | Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism |
| AU2003268235A1 (en) * | 2002-09-09 | 2004-03-29 | Mitochroma Research, Inc. | Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation |
| US6884454B2 (en) | 2002-10-21 | 2005-04-26 | Julio Lionel Pimentel | Appetite suppressing diet bar |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP1605950A4 (en) | 2003-03-06 | 2008-01-09 | Accera Inc | NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS |
| EP1648952B1 (en) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| US20050013884A1 (en) * | 2003-07-16 | 2005-01-20 | Rennels M. Scott | Compositions and methods for treating heart disease |
| US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
| US20060252775A1 (en) | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
| US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| NZ569235A (en) | 2005-12-15 | 2011-12-22 | Nestec Sa | Compositions and methods for preserving brain function using medium chain triglycerides |
| US7807718B2 (en) | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
-
2001
- 2001-05-01 US US09/845,741 patent/US20020006959A1/en not_active Abandoned
- 2001-05-01 AT AT01930965T patent/ATE425750T1/de active
- 2001-05-01 ES ES09001380T patent/ES2752800T3/es not_active Expired - Lifetime
- 2001-05-01 EP EP10181854A patent/EP2319508A1/en not_active Withdrawn
- 2001-05-01 DK DK01930965T patent/DK1292294T3/da active
- 2001-05-01 DE DE60138019T patent/DE60138019D1/de not_active Expired - Lifetime
- 2001-05-01 AU AU2001257451A patent/AU2001257451A1/en not_active Abandoned
- 2001-05-01 WO PCT/US2001/013955 patent/WO2001082928A1/en not_active Ceased
- 2001-05-01 JP JP2001579803A patent/JP2003531857A/ja active Pending
- 2001-05-01 EP EP09001380.6A patent/EP2065041B1/en not_active Expired - Lifetime
- 2001-05-01 ES ES01930965T patent/ES2323940T3/es not_active Expired - Lifetime
- 2001-05-01 EP EP01930965A patent/EP1292294B1/en not_active Expired - Lifetime
- 2001-05-01 PT PT01930965T patent/PT1292294E/pt unknown
-
2006
- 2006-01-13 US US11/331,673 patent/US20060122270A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,679 patent/US8426468B2/en not_active Expired - Fee Related
- 2012-05-07 JP JP2012105692A patent/JP5701245B2/ja not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0597785A (ja) * | 1990-02-23 | 1993-04-20 | Sigma Tau Ind Farmaceut Riunite Spa | （Ｒ）（−）−カルニチンおよびアシル−（Ｒ）（−）カルニチンとβ−ヒドロキシ酪酸とのエステル |
| JPH06287138A (ja) * | 1993-04-02 | 1994-10-11 | Green Cross Corp:The | アルツハイマー病予防治療剤 |
| WO1998041201A1 (en) * | 1997-03-17 | 1998-09-24 | Btg International Limited | Therapeutic compositions |
Non-Patent Citations (4)
| Title |
|---|
| ACTA. PAEDIATR. SIN., vol. 40, no. 2, JPN6011021573, 1999, pages 97 - 100, ISSN: 0001906419 * |
| J. LIPID. RES., vol. 37, JPN6012043608, 1996, pages 708 - 726, ISSN: 0002309956 * |
| J. NUTR., vol. 127, JPN6011021575, 1997, pages 1061 - 1067, ISSN: 0001906420 * |
| NEUROLOGY, vol. 47, JPN6011021577, 1996, pages 705 - 711, ISSN: 0001906421 * |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10111849B2 (en) | 2000-05-01 | 2018-10-30 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US9603823B2 (en) | 2000-05-01 | 2017-03-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| JP2009524587A (ja) * | 2005-12-15 | 2009-07-02 | ネステク ソシエテ アノニム | 脳機能を維持するための組成物及び方法 |
| JP2009532496A (ja) * | 2006-04-03 | 2009-09-10 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
| JP2018080175A (ja) * | 2006-04-03 | 2018-05-24 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
| JP2013082716A (ja) * | 2006-04-03 | 2013-05-09 | Accera Inc | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
| KR20150018897A (ko) * | 2006-04-03 | 2015-02-24 | 액세라인크 | 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도 |
| JP2016121128A (ja) * | 2006-04-03 | 2016-07-07 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
| KR101634083B1 (ko) | 2006-04-03 | 2016-06-28 | 액세라인크 | 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도 |
| US9375453B2 (en) | 2007-03-28 | 2016-06-28 | Aker Biomarine Antarctic As | Methods for producing bioeffective krill oil compositions |
| US9078905B2 (en) | 2007-03-28 | 2015-07-14 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
| US9119864B2 (en) | 2007-03-28 | 2015-09-01 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
| US9320765B2 (en) | 2007-03-28 | 2016-04-26 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
| US9072752B1 (en) | 2007-03-28 | 2015-07-07 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
| US9034388B2 (en) | 2007-03-28 | 2015-05-19 | Aker Biomarine Antartic As | Bioeffective krill oil compositions |
| US9028877B2 (en) | 2007-03-28 | 2015-05-12 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
| US10105338B2 (en) | 2007-07-31 | 2018-10-23 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| US9175345B2 (en) | 2007-07-31 | 2015-11-03 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| JP2010535037A (ja) * | 2007-07-31 | 2010-11-18 | アクセラ・インコーポレーテッド | 認知機能減少の治療のためのゲノム試験およびケトン体生成化合物の使用 |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| JP2011528667A (ja) * | 2008-07-18 | 2011-11-24 | ダート ニューロサイエンス エルエルシー | 記憶剤の評価のための方法およびシステム |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| JP2015110626A (ja) * | 2009-12-30 | 2015-06-18 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | アルツハイマー病と加齢脳に対する補充療法 |
| JP2021107394A (ja) * | 2012-06-15 | 2021-07-29 | ヴィタフロ （インターナショナル） リミテッドＶｉｔａｆｌｏ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） Ｌｔｄ | 栄養製品 |
| US11344522B2 (en) | 2012-06-15 | 2022-05-31 | Vitaflow (International) Ltd | Nutritional product |
| US12257222B2 (en) | 2012-06-15 | 2025-03-25 | Vitaflo (International) Ltd | Nutritional product |
| JP2017505786A (ja) * | 2014-02-11 | 2017-02-23 | ファーネクストＰｈａｒｎｅｘｔ | 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用 |
| JP2019500024A (ja) * | 2015-12-04 | 2019-01-10 | ネステク ソシエテ アノニム | 認知を改善するための方法 |
| KR20200132950A (ko) * | 2018-03-15 | 2020-11-25 | 세레신 인코포레이티드 | 높은 약물 로딩의 중쇄 트리글리세라이드를 갖는 약학적 조성물 및 이와 관련된 방법 |
| JP2021518355A (ja) * | 2018-03-15 | 2021-08-02 | セレシン・インコーポレーテッド | 高い薬物充填量の中鎖脂肪酸トリグリセリドを有する医薬組成物およびそれに関連する方法 |
| JP7562414B2 (ja) | 2018-03-15 | 2024-10-07 | セレシン・インコーポレーテッド | 高い薬物充填量の中鎖脂肪酸トリグリセリドを有する医薬組成物およびそれに関連する方法 |
| KR102868233B1 (ko) | 2018-03-15 | 2025-10-13 | 세레신 인코포레이티드 | 높은 약물 로딩의 중쇄 트리글리세라이드를 갖는 약학적 조성물 및 이와 관련된 방법 |
| JP2022523550A (ja) * | 2019-03-04 | 2022-04-25 | セレシン・インコーポレーテッド | バイオアベイラビリティが改善した中鎖脂肪酸トリグリセリド製剤およびそれに関連する方法 |
| JP7573541B2 (ja) | 2019-03-04 | 2024-10-25 | セレシン・インコーポレーテッド | バイオアベイラビリティが改善した中鎖脂肪酸トリグリセリド製剤およびそれに関連する方法 |
| JP2023534919A (ja) * | 2020-07-23 | 2023-08-15 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 認知機能を改善させるためのｍｃｔ配合物、並びにかかる配合物の製造及び使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60138019D1 (de) | 2009-04-30 |
| WO2001082928A1 (en) | 2001-11-08 |
| AU2001257451A1 (en) | 2001-11-12 |
| ES2752800T3 (es) | 2020-04-06 |
| EP1292294A1 (en) | 2003-03-19 |
| US20120196932A1 (en) | 2012-08-02 |
| JP2012188431A (ja) | 2012-10-04 |
| EP2065041A1 (en) | 2009-06-03 |
| JP5701245B2 (ja) | 2015-04-15 |
| EP1292294A4 (en) | 2004-04-14 |
| WO2001082928A9 (en) | 2006-06-15 |
| PT1292294E (pt) | 2009-06-01 |
| US8426468B2 (en) | 2013-04-23 |
| ES2323940T3 (es) | 2009-07-28 |
| US20020006959A1 (en) | 2002-01-17 |
| DK1292294T3 (da) | 2009-06-22 |
| US20060122270A1 (en) | 2006-06-08 |
| AU2001257451A8 (en) | 2006-11-09 |
| ATE425750T1 (de) | 2009-04-15 |
| EP2065041B1 (en) | 2019-07-31 |
| EP2319508A1 (en) | 2011-05-11 |
| EP1292294B1 (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5701245B2 (ja) | アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用 | |
| US10111849B2 (en) | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II | |
| US20070179197A1 (en) | Compositions and methods for improving or preserving brain function | |
| US9795580B2 (en) | Ketone supplements for treatment of angelman syndrome | |
| EP2691086B1 (en) | Compositions for the treatment of neurologic disorders | |
| JP2018080175A (ja) | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 | |
| CN102958516A (zh) | 白藜芦醇或其他羟基化均二苯代乙烯用于保护认知功能的用途 | |
| KR101734152B1 (ko) | 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체 | |
| US20130230503A1 (en) | Method and preparation for the treatment or prevention of anxiety or neurogenesis | |
| JP2006519843A (ja) | 新規化学物質及び代謝異常の治療におけるそれらの使用法 | |
| HK1194665B (en) | Compositions for the treatment of neurologic disorders | |
| HK1157580A (en) | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110427 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110721 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110728 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111027 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20111209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120507 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120620 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120824 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131126 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131129 |